Nanodiamonds-mediated doxorubicin nuclear delivery to inhibit lung metastasis of breast cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24016858.
- Also identified by DOI 10.1016/j.biomaterials.2013.08.056.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lung metastasis is one of the greatest challenges for breast cancer treatment. Here, a nanodiamonds (NDs)-mediated doxorubicin (DOX) delivery system was first designed to inhibit the lung metastasis of breast cancer effectively. DOX was non-covalently bound to NDs via physical adsorption in an aqueous solution, then DSPE-PEG 2K was coated to the NDs-DOX complex (NDX) to increase the dispersibility and prolong the circulation time. DSPE-PEG 2K coating NDX (DNX) displayed high drug loading and excellent ability to deliver DOX to the nucleus, thereby significantly enhancing cytotoxicity and inducing cell apoptosis. Furthermore, DNX showed good histocompatibility and could improve drug accumulation in lung, as a result, markedly inhibited the lung metastasis of breast cancer. The high anti-metastasis efficacy with the decreased systemic toxicity suggested that DNX could be a promising drug delivery system for the therapy of lung metastasis of breast cancer.
Medical subject headings
- Antibiotics, Antineoplastic
- Breast Neoplasms
- Doxorubicin
- Drug Carriers
- Lung Neoplasms
- Nanodiamonds